The Medicaid drug program wasted $329 million nationwide in 2009 from states all too frequently reimbursing for a version of a drug that is more costly than another product with the exact same active ingredient, dose, form and bottle size.

Controlling costs in the short run is a vital part of efforts to reform the U.S. health care system, but it should not come at the expense of future innovations.

Failing to distinguish between licensed online pharmacies (Canadian or otherwise), which require a valid prescription and sell safe medications, and rogue online pharmacies, which sell lethal fake medicines or flout prescription requirements, means poor patients have less information to make good choices about the drugs they require.

Adoption of a stakeholder approach is likely to undermine essentialresearch and developmentwhile doing little to curtail the HIV/AIDS epidemic.

The use of cost-effectiveness criteria, while lowering the cost of health care in the short term, threatens to harm future patients by stifling vital medical innovations.

Cases that will have profound effects on ObamaCare's future are already pending before the Supreme Court. The justices will get these cases right.

Americans pay more--often a lot more--for drugs than Canadians and Europeans. That is unfair, but wholesale importation of drugs from these locations isn't the answer.

H.R. 4489 focuses on a specific market: prescription drug coverage for federal employees; the legislation would impose a wide variety of restrictions, controls, and mandates.